- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilars Articles for the Week of December 9
The Center for Biosimilars® recaps the top stories for the week of December 9, 2019.
Transcript
Hi, I’m Laura Joszt for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of December 9, 2019.
Number 5: Increased spending on new oncology and autoimmune drugs was partially offset by a continued increase in the use of generics, according to a recent report from CMS.
Number 4: During this week’s 61st meeting of the American Society of Hematology, researchers reported on eculizumab, a prospective biosimilar, and a long-acting successor.
Number 3: Sanofi announced that it will stop research and development on diabetes drugs, but it will keep a proposed biosimilar of insulin aspart in its pipeline as a registration-phase molecule.
Number 2: An agreement on the United States—Mexico–Canada Agreement has been reached, and it excludes controversial terms for biologics.
Number 1: The FDA has approved Amgen’s infliximab biosimilar, Avsola, the fourth biosimilar infliximab and the 26th US biosimilar.
Finally, last week, our e-newsletter asked how great an impact you think subcutaneously administered biosimilar infliximab will have on clinical practice.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Challenges, Obstacles, and Future Directions for Anti-TNF Biosimilars in IBD
November 9th 2024A review article on tumor necrosis factor (TNF)-α inhibitors in inflammatory bowel disease (IBD) outlined current use of anti-TNF originators and biosimilars, their efficacy and safety, the benefits and challenges of biosimilars, and the future of biosimilars in IBD.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Eye on Pharma: Henlius, Organon Updates; Meitheal Portfolio Expansion; Celltrion Zymfentra Data
November 5th 2024Henlius and Organon’s pertuzumab biosimilar met phase 3 goals; Meitheal expanded its US biosimilars; Celltrion’s subcutaneous infliximab (Zymfentra) showed monotherapy could be as effective as combination therapy for inflammatory bowel disease.
